Pfizer drags Aurobindo Pharma, Dr Reddy's to US court over cancer drug
Pfizer filed a possible patent infringement petition against both companies in the United States District Court for the District of Delaware and two counts last week
- Nov 17, 2020,
- Updated Nov 17, 2020 5:16 PM IST
Pfizer Inc and its group companies have moved a US court against Hyderabad-based Aurobindo Pharma Ltd and Dr Reddy's Laboratories (DRL) alleging that the Indian drug makers were seperately planning to launch generic versions of its bestseller breast cancer drug Ibrance (palbociclib) before expiration of its patent.
Pfizer filed a possible patent infringement petition against both companies in the United States District Court for the District of Delaware and two counts last week.
The company's multi-billion-dollar drug Ibrance had logged around $5 billion in revenues worldwide comprising $3.25 billion in the USA in 2019, according to its 2019 annual report.
(With inputs from PTI.)
Pfizer Inc and its group companies have moved a US court against Hyderabad-based Aurobindo Pharma Ltd and Dr Reddy's Laboratories (DRL) alleging that the Indian drug makers were seperately planning to launch generic versions of its bestseller breast cancer drug Ibrance (palbociclib) before expiration of its patent.
Pfizer filed a possible patent infringement petition against both companies in the United States District Court for the District of Delaware and two counts last week.
The company's multi-billion-dollar drug Ibrance had logged around $5 billion in revenues worldwide comprising $3.25 billion in the USA in 2019, according to its 2019 annual report.
(With inputs from PTI.)